Previous 10 | Next 10 |
NEW YORK and VIENNA, Austria, Aug. 03, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that it will release its second quarter 2023 financial ...
2023-06-01 10:07:16 ET Gainers: Nanobiotix ( NBTX ) +17% . Veeva Systems ( VEEV ) +13% . Biohaven ( BHVN ) +12% . Rockwell Medical ( RMTI ) +11% . Quipt Home Medical ( QIPT ) +9% . Losers: Lexicon Pharmaceuticals ( LXRX ...
2023-06-01 02:06:48 ET HOOKIPA Pharma ( NASDAQ: HOOK ) prices an underwritten public offering of ~22.9M common shares and 15,268 shares of its non-voting Series A-2 convertible preferred stock. The public offering price of each share of common stock is $1.31 and the public...
NEW YORK and VIENNA, Austria, May 31, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (Nasdaq: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the pricing of an underwritten public offering of 22,900...
2023-05-31 19:47:53 ET This week has seen the stock market flip-flop, including the volatile world of penny stocks . Investors, especially those interested in high-risk, high-reward low-priced stocks, are attentively tracking the developments in Washington. The impending vote on the deb...
HB-200 in combination with pembrolizumab doubled the objective response rate of 1 st -line pembrolizumab for patients with recurrent/metastatic head and neck cancer HOOKIPA is preparing to start a pivotal trial of HB-200 in combination with pembrolizumab as 1 st -line trea...
2023-05-11 09:32:47 ET HOOKIPA Pharma press release ( NASDAQ: HOOK ): Q1 GAAP EPS of -$0.27 misses by $0.03 . Revenue of $3.17M (+120.1% Y/Y) misses by $1.34M . For further details see: HOOKIPA Pharma GAAP EPS of -$0.27 misses by $0.03, revenue of $3.17M ...
HOOKIPA on track to report Phase 2 data on HB-200 for head and neck cancer in combination with pembrolizumab in 2Q 2023 Phase 1 clinical trials initiated for two programs (HB-300 for advanced prostate cancer and Gilead-partnered HB-400 for chronic hepatitis B) HB-700 for KRAS-muta...
NEW YORK and VIENNA, Austria, May 09, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that the first person has been dosed in a Gilead-led Pha...
2023-04-26 15:17:26 ET Shares of immunotherapy company Hookipa Pharma ( NASDAQ: HOOK ) rose for the fourth consecutive session after announcing that it is scheduled to present an overview of its ongoing Phase 1/2 trial for prostate cancer drug HB-300 at an upcoming medical event. ...
News, Short Squeeze, Breakout and More Instantly...
Director Dr. Malte Peters named Chief Executive Officer and Director Terry Coelho named Executive Vice President and Chief Financial Officer Company is conducting a review of its business operations and strategy to determine best path to create shareholder value and realize the full potential...
A look at the top 10 most actives in the United States Longeveron Inc. (LGVN) rose 69.0% to $4.8499 on volume of 46,980,986 shares Virpax Pharmaceuticals Inc. (VRPX) rose 161.5% to $3.0333 on volume of 46,199,502 shares Maxeon Solar Technologies Ltd. (MAXN) fell 0.6% to $0.2464 on volume ...
2024-07-09 09:02:05 ET Hookipa Pharma Inc (HOOK) announced stock split at a ratio of 1-for-10 on 2024-07-10 ... Full story available on KlickAnalytics.com